HRP20031028A2 - Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds - Google Patents

Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds Download PDF

Info

Publication number
HRP20031028A2
HRP20031028A2 HR20031028A HRP20031028A HRP20031028A2 HR P20031028 A2 HRP20031028 A2 HR P20031028A2 HR 20031028 A HR20031028 A HR 20031028A HR P20031028 A HRP20031028 A HR P20031028A HR P20031028 A2 HRP20031028 A2 HR P20031028A2
Authority
HR
Croatia
Prior art keywords
phenyl
heteroaryl
alkyl
naphthyl
hydrogen
Prior art date
Application number
HR20031028A
Other languages
English (en)
Croatian (hr)
Inventor
Brendel Joachim
Bhme Thomas
Peukert Stefan
Kleemann Heinz-Werner
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of HRP20031028A2 publication Critical patent/HRP20031028A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR20031028A 2001-06-12 2002-05-31 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds HRP20031028A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2002/005956 WO2002100825A2 (de) 2001-06-12 2002-05-31 Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe

Publications (1)

Publication Number Publication Date
HRP20031028A2 true HRP20031028A2 (en) 2005-10-31

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20031028A HRP20031028A2 (en) 2001-06-12 2002-05-31 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds

Country Status (40)

Country Link
US (2) US6903216B2 (OSRAM)
EP (1) EP1399423B9 (OSRAM)
JP (1) JP4422477B2 (OSRAM)
KR (1) KR100863924B1 (OSRAM)
CN (1) CN1247544C (OSRAM)
AR (1) AR036045A1 (OSRAM)
AT (1) ATE378318T1 (OSRAM)
AU (1) AU2002316939B2 (OSRAM)
BG (1) BG108415A (OSRAM)
BR (1) BR0210374A (OSRAM)
CA (1) CA2450076C (OSRAM)
CO (1) CO5540283A2 (OSRAM)
CR (1) CR7140A (OSRAM)
CY (1) CY1107427T1 (OSRAM)
CZ (1) CZ20033361A3 (OSRAM)
DE (2) DE10128331A1 (OSRAM)
DK (1) DK1399423T3 (OSRAM)
EC (1) ECSP034883A (OSRAM)
EE (1) EE05196B1 (OSRAM)
ES (1) ES2295360T3 (OSRAM)
HR (1) HRP20031028A2 (OSRAM)
HU (1) HUP0400159A3 (OSRAM)
IL (2) IL159247A0 (OSRAM)
MA (1) MA27037A1 (OSRAM)
MX (1) MXPA03010875A (OSRAM)
MY (1) MY138341A (OSRAM)
NO (1) NO20035450D0 (OSRAM)
NZ (1) NZ530081A (OSRAM)
OA (1) OA12631A (OSRAM)
PE (1) PE20021066A1 (OSRAM)
PL (1) PL364371A1 (OSRAM)
PT (1) PT1399423E (OSRAM)
RS (1) RS97703A (OSRAM)
RU (1) RU2293727C2 (OSRAM)
SK (1) SK15222003A3 (OSRAM)
TN (1) TNSN03134A1 (OSRAM)
TW (1) TWI304400B (OSRAM)
UA (1) UA75412C2 (OSRAM)
WO (1) WO2002100825A2 (OSRAM)
ZA (1) ZA200308520B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
EP1500650A4 (en) * 2002-04-26 2006-08-23 Ishihara Sangyo Kaisha PYRIDINE COMPOUNDS OR SALTS THEREOF AND HERBICIDES CONTAINING SAME
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
EA200600203A1 (ru) 2003-08-08 2006-08-25 Янссен Фармацевтика, Н. В. Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
MX2007003623A (es) 2004-09-24 2007-09-11 Johnson & Johnson Compuestos sulfonamida.
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
CA2650391C (en) * 2006-04-27 2015-12-15 Sanofi-Aventis Deutschland Gmbh Inhibitors of the task-1 and task-3 ion channel
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
PL2448909T3 (pl) * 2009-06-29 2013-09-30 Merz Pharma Gmbh & Co Kgaa Sposób wytwarzania 1-amino-1,3,3,5,5-pentametylocykloheksanu
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
RU2414893C1 (ru) * 2009-11-11 2011-03-27 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Четвертичное аммониевое производное новокаина, обладающее противоаритмической активностью, и способ его получения
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (OSRAM) 2011-07-01 2018-04-28
AU2013203252B2 (en) 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
US12357626B2 (en) 2017-08-07 2025-07-15 Amenis Bioscience, Inc. Anthranilic acid-based compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118595A (zh) 1993-12-27 1996-03-13 卫材株式会社 氨茴酸衍生物
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
BR9911914B1 (pt) * 1998-07-08 2010-10-19 n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
CA2341678C (en) 1998-09-01 2009-10-13 Bristol-Myers Squibb Company Potassium channel inhibitors and method
TR200103696T2 (tr) * 1999-06-24 2002-06-21 Smithkline Beecham Corporation Makrofaj temizleyici reseptör antagonistleri.
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
KR100863924B1 (ko) 2008-10-17
DE50211213D1 (de) 2007-12-27
EE05196B1 (et) 2009-08-17
KR20040030668A (ko) 2004-04-09
US7235664B2 (en) 2007-06-26
EP1399423B9 (de) 2008-02-27
BG108415A (en) 2004-07-30
RS97703A (sr) 2006-12-15
EE200300558A (et) 2004-02-16
CY1107427T1 (el) 2012-12-19
NO20035450D0 (no) 2003-12-08
PT1399423E (pt) 2008-02-07
DK1399423T3 (da) 2008-03-17
HUP0400159A2 (hu) 2004-07-28
HK1065316A1 (en) 2005-02-18
CO5540283A2 (es) 2005-07-29
ES2295360T3 (es) 2008-04-16
CR7140A (es) 2004-04-15
UA75412C2 (en) 2006-04-17
BR0210374A (pt) 2004-07-13
ECSP034883A (es) 2004-01-28
EP1399423B1 (de) 2007-11-14
CA2450076C (en) 2010-11-30
CN1247544C (zh) 2006-03-29
RU2004100302A (ru) 2005-04-10
RU2293727C2 (ru) 2007-02-20
TWI304400B (en) 2008-12-21
US20050137200A1 (en) 2005-06-23
WO2002100825A2 (de) 2002-12-19
MY138341A (en) 2009-05-29
CA2450076A1 (en) 2002-12-19
PE20021066A1 (es) 2003-01-21
AR036045A1 (es) 2004-08-04
TNSN03134A1 (en) 2005-12-23
IL159247A0 (en) 2004-06-01
EP1399423A2 (de) 2004-03-24
SK15222003A3 (sk) 2004-06-08
HUP0400159A3 (en) 2008-10-28
CZ20033361A3 (cs) 2004-05-12
ZA200308520B (en) 2004-09-06
MXPA03010875A (es) 2004-02-17
US6903216B2 (en) 2005-06-07
PL364371A1 (en) 2004-12-13
JP2004533464A (ja) 2004-11-04
CN1529695A (zh) 2004-09-15
ATE378318T1 (de) 2007-11-15
AU2002316939B2 (en) 2006-11-23
IL159247A (en) 2010-06-16
WO2002100825A3 (de) 2003-12-11
US20030114499A1 (en) 2003-06-19
OA12631A (fr) 2006-06-14
MA27037A1 (fr) 2004-12-20
DE10128331A1 (de) 2002-12-19
JP4422477B2 (ja) 2010-02-24
NZ530081A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
HRP20031028A2 (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds
RU2283833C2 (ru) Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
KR101444489B1 (ko) 심혈관 질환을 예방 및 치료하기 위한 화합물
RU2275360C2 (ru) Ортозамещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции
HRP20030436A2 (en) Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, theiruse as a medicament, and pharmaceutical preparations containing these compounds
US8906946B2 (en) TRPM8 receptor antagonists
JP2007525482A (ja) イオンチャネルリガンドとしてのアミド化合物およびその使用
MXPA06003951A (es) Derivados de amida como ligandos del canal de ion y composiciones farmaceuticas y sus metodos de uso.
JP4039625B2 (ja) アシルアミノアルキル置換ベンゼンスルホンアミド誘導体、それらの製造、それらの使用、および、それらを含む医薬製剤
JP2002520387A (ja) ２，５−置換されたベンゼンスルホニル尿素および−チオ尿素、それらの製法、それらの使用およびそれらを含有する医薬製剤
HK1064663B (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
CN120965608A (zh) 一种苯磺酰胺类化合物及其制备方法和应用
WO2021248256A1 (zh) 吡唑类化合物及其制备方法、用途和药物组合物

Legal Events

Date Code Title Description
A1OB Publication of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, DE

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100529

Year of fee payment: 9

ODBC Application rejected